Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 33 min ago
Peer-reviewedLicence not statedJournal of Clinical Oncology

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial

  • Tanios Bekaii‐Saab1
  • Davide Melisi2
  • Hanneke W. Wilmink3
  • Carlo Garufi4
  • Nguyen Tran5
  • Giampaolo Tortora6
  • Filippo de Braud7
  • Jan‐Erik Frödin8
  • Sara Lonardi9
  • Emily Lin10
  • Hani Babiker11
  • Bruce Shih-Li Lin12
15 more authors
  • Lorenzo Fornaro13
  • Andrés Muñoz Martín14
  • John A. Bridgewater15
  • Jennifer Jane Knox16
  • Judith de Vos‐Geelen17
  • Martin Scott-Brown18
  • Maria Luisa Veronese19
  • Sonia Ioannidis19
  • Aidan G. Gilmartin20
  • John Edward Janik20
  • Yufei Guo20
  • Junji Furuse21
  • Tatsuya Ioka22
  • Lorenza Rimassa23,24
  • Arndt Vogel25
25 affiliations
  1. 1Mayo Clinic, Phoenix, AZ
  2. 2University of Verona, Verona, Italy
  3. 3Amsterdam UMC, Amsterdam, the Netherlands
  4. 4Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy
  5. 5Mayo Clinic, Rochester, MN
  6. 6Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  7. 7Istituto Nazionale Tumori, Milan, Italy
  8. 8Karolinska University Hospital, Stockholm, Sweden
  9. 9Veneto Institute of Oncology IOV—IRCCS, Padua, Italy
  10. 10Providence Cancer Institute, Portland, OR
  11. 11Mayo Clinic, Jacksonville, FL
  12. 12Virginia Mason Medical Center, Seattle, WA
  13. 13Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
  14. 14Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain
  15. 15CL Cancer Institute, London, United Kingdom
  16. 16University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
  17. 17Maastricht University Medical Center, GROW—Research Institute for Oncology & Reproduction, Maastricht, the Netherlands
  18. 18University Hospital Coventry and Warwickshire, Coventry, United Kingdom
  19. 19Incyte Biosciences International Sàrl, Morges, Switzerland
  20. 20Incyte Corporation, Wilmington, DE
  21. 21Kanagawa Cancer Center, Yokohama, Japan
  22. 22Yamaguchi University Hospital, Ube, Japan
  23. 23Department of Biomedical Sciences, Humanitas University, Milan, Italy
  24. 24Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy
  25. 25Hannover Medical School, Hannover, Germany
Open at sourcePDFDOICite

Related

  1. Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib
    Piotr Kawczak, Tomasz Bączek
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Modified Sullivan-type segment III hepatojejunostomy for radiologically presumed unresectable hilar cholangiocarcinoma: a technical case report
    Journal of surgical case reportsPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Complete response in unresectable HER2+ cholangiocarcinoma with histotripsy and systemic therapy followed by liver transplantation: a case report.
    Tiffany M Juarez, Jimmy Ton, Ivan Babin +9
    Frontiers in oncologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCCrossref
  4. Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinoma
    Chi Ma, Kun Feng, Jun Zhou
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMCCrossrefEurope PMC
  5. Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial
    Ji Ma, Tao Wang, Yichen Zheng +7
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaCrossref

Cite

BibTeXRIS
BibTeX
@article{bekaiisaab2026pemigatinib,
  title = {{Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial}},
  author = {Tanios Bekaii‐Saab and Davide Melisi and Hanneke W. Wilmink and Carlo Garufi and Nguyen Tran and Giampaolo Tortora and Filippo de Braud and Jan‐Erik Frödin and Sara Lonardi and Emily Lin and Hani Babiker and Bruce Shih-Li Lin and Lorenzo Fornaro and Andrés Muñoz Martín and John A. Bridgewater and Jennifer Jane Knox and Judith de Vos‐Geelen and Martin Scott-Brown and Maria Luisa Veronese and Sonia Ioannidis and Aidan G. Gilmartin and John Edward Janik and Yufei Guo and Junji Furuse and Tatsuya Ioka and Lorenza Rimassa and Arndt Vogel},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  month = jun,
  doi = {10.1200/jco-26-00788},
  url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13641261/},
}
RIS
TY  - JOUR
TI  - Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
AU  - Tanios Bekaii‐Saab
AU  - Davide Melisi
AU  - Hanneke W. Wilmink
AU  - Carlo Garufi
AU  - Nguyen Tran
AU  - Giampaolo Tortora
AU  - Filippo de Braud
AU  - Jan‐Erik Frödin
AU  - Sara Lonardi
AU  - Emily Lin
AU  - Hani Babiker
AU  - Bruce Shih-Li Lin
AU  - Lorenzo Fornaro
AU  - Andrés Muñoz Martín
AU  - John A. Bridgewater
AU  - Jennifer Jane Knox
AU  - Judith de Vos‐Geelen
AU  - Martin Scott-Brown
AU  - Maria Luisa Veronese
AU  - Sonia Ioannidis
AU  - Aidan G. Gilmartin
AU  - John Edward Janik
AU  - Yufei Guo
AU  - Junji Furuse
AU  - Tatsuya Ioka
AU  - Lorenza Rimassa
AU  - Arndt Vogel
PY  - 2026
DA  - 2026/06/01
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-26-00788
UR  - https://pmc.ncbi.nlm.nih.gov/articles/PMC13641261/
SN  - 0732-183X
SN  - 1527-7755
ER  -